Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions
…, WP Fendler, K Herrmann, CH Pfob… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed …
68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study
…, TA Hope, S Okamoto, CH Pfob… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The interobserver agreement for 68 Ga-PSMA-11 PET/CT study interpretations in patients
with prostate cancer is unknown. Methods: 68 Ga-PSMA-11 PET/CT was performed in 50 …
with prostate cancer is unknown. Methods: 68 Ga-PSMA-11 PET/CT was performed in 50 …
Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
CH Pfob, S Ziegler, FP Graner, M Köhner… - European journal of …, 2016 - Springer
Purpose Positron emission tomography (PET) agents targeting the prostate-specific
membrane antigen (PSMA) are currently under broad clinical and scientific investigation. Ga-PSMA …
membrane antigen (PSMA) are currently under broad clinical and scientific investigation. Ga-PSMA …
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
…, F Kurtz, B Feuerecker, C D'Alessandria, C Pfob… - European Journal of …, 2018 - Springer
Purpose Patients with carcinoma in situ (CIS) of the bladder refractory to bacillus Calmette-Guérin
(BCG) treatment are usually treated with cystectomy. Therefore, new treatment options …
(BCG) treatment are usually treated with cystectomy. Therefore, new treatment options …
[HTML][HTML] [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience
…, HJ Wester, T Janzen, C Lapa, CH Pfob… - European Journal of …, 2023 - Springer
Purpose The clinical success non-invasive imaging of CXCR4 expression using [ 68 Ga]Ga-PentixaFor-PET
warrants an expansion of the targeting concept towards conventional …
warrants an expansion of the targeting concept towards conventional …
[HTML][HTML] Molecular imaging in multiple myeloma—novel PET radiotracers improve patient management and guide therapy
J von Hinten, M Kircher, A Dierks, CH Pfob… - Frontiers in Nuclear …, 2022 - frontiersin.org
Due to its proven value in imaging of multiple myeloma (MM), including staging, prognostication,
and assessment of therapy response, 2-deoxy-2-[ 18 F]fluoro-D-glucose (FDG) positron …
and assessment of therapy response, 2-deoxy-2-[ 18 F]fluoro-D-glucose (FDG) positron …
Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga] Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer
…, R Beck, G Wienand, A Dierks, CH Pfob… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Because of the need for radiolabeled theranostics for the detection and treatment of
medullary thyroid cancer (MTC), and the yet unresolved stability issues of minigastrin analogs …
medullary thyroid cancer (MTC), and the yet unresolved stability issues of minigastrin analogs …
An intrapatient dosimetry comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
A Rinscheid, A Gäble, G Wienand, C Pfob… - Journal of Nuclear …, 2023 - Soc Nuclear Med
As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing
the absorbed dose to normal organs while maintaining high tumor radiation doses becomes …
the absorbed dose to normal organs while maintaining high tumor radiation doses becomes …
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
L Steinhelfer, L Lunger, L Cala, CH Pfob… - Journal of Nuclear …, 2024 - Soc Nuclear Med
β-emitting 177 Lu targeting prostate-specific membrane antigen (PSMA) is an approved
treatment option for metastatic castration-resistant prostate cancer. Data on its long-term …
treatment option for metastatic castration-resistant prostate cancer. Data on its long-term …
CCK2 Receptor–Targeted PET/CT in Medullary Thyroid Cancer Using [68Ga] Ga-DOTA-CCK-66
…, A Dierks, G Wienand, CH Pfob… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Medullary thyroid cancer (MTC), a neuroendocrine tumor arising from the parafollicular cells
of the thyroid gland, accounts for approximately 1%-2% of all thyroid cancers (1). Only …
of the thyroid gland, accounts for approximately 1%-2% of all thyroid cancers (1). Only …